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survival time is less than 6 months, with 
a bleak 5-year survival rate of 8%, making 
it one of the most lethal malignancies in 
humans.[1] Lack of early symptoms and 
reliable screening tests for early detec-
tion are major reasons why over 85% of 
PDAC patients are inoperable at the time 
of diagnosis.[2]
Since access to tumor biopsies in 
pancreatic cancer (PaCa) is quite chal-
lenging due to its anatomical positions, 
biomarkers are required to provide better 
diagnosis and explore alternative thera-
pies. One avenue that holds promise in 
developing accurate predictive tools and 
pharmacodynamic biomarkers to guide 
patient care is the analysis of circulating 
tumor cells (CTCs).[3–9] Detection, quan-
tification, and molecular characterization 
of CTCs in peripheral blood have been 
recognized as highly valuable emerging 
techniques in the diagnosis of cancer 
and detection of metastasis.[3,7,10,11] CTCs 
are cells that extravasate from the pri-
mary tumor, enter the blood stream, 
enabling their transportation to distant 
sites and potential formation of meta-
static tumors.[2,3,12] CTCs may enter the blood circulation in 
two ways: by passive shedding of tumor cells from the primary 
tumor, which may occur in large numbers and in early stages 
of tumor formation, or by an active mechanism involving the 
Although isolation of circulating tumor cells (CTCs) from pancreatic 
adenocarcinoma patients is feasible, investigating their clinical utility has 
proven less successful than other cancers due to the limitations of epithelial 
cellular adhesion molecule (EpCAM)-only based CTC assays. An integrated 
technology- and biology-based approach using a microfluidic “Carpet 
Chip” is presented to study the biological relevance of heterogeneous CTC 
populations. Both epithelial CTCs (EpCs) and epithelial-to-mesenchymal 
transition (EMT)-like CTCs (EMTCs) are isolated simultaneously from the 
whole blood of pancreatic cancer (PaCa) patients (n = 35) by separately 
targeting two surface markers: EpCAM and CD133. Recovery of cancer 
cell lines spiked into whole blood is ≥97% with >76% purity. Thirty-four 
patients had ≥5 EpCs mL−1 and 35 patients had ≥15 EMTCs mL−1. Overall, 
significantly higher numbers of EMTCs than EpCs are recovered, reflecting 
the aggressive nature of PaCa. Furthermore, higher numbers of EMTCs are 
observed in patients with lymph node involvement compared to patients 
without. Gene expression profiling of CTCs from 17 patients reveals that 
CXCR1 is significantly upregulated in EpCs, while known stem cell markers 
POU5F1/Oct-4 and MYC are upregulated in EMTCs. In conclusion, successful 
isolation and genomic profiling of heterogeneous CTC populations are 
demonstrated, revealing genetic signatures relevant to patient outcomes.
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1. Introduction
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause 
of cancer-related death in the United States.[1] The median 
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epithelial-to-mesenchymal transition (EMT).[2] EMT is a com-
plex molecular and cellular program by which cells of epithe-
lial origin lose their apical-basal polarity and adhesiveness to 
neighboring cells and gain mesenchymal features including 
aggressiveness, motility, invasiveness, and resistance to apop-
tosis.[2,5] Thus, EMT can be molecularly defined by tumor cells 
losing intracellular adhesions, with down-
regulation of epithelial markers (e.g., epi-
thelial cell adhesion molecule (EpCAM) and 
cytokeratins) and upregulation of mesen-
chymal markers (e.g., CD133, vimentin).[13]
Cancer stem cells (CSCs) and cells 
undergoing EMT play important roles in 
tumorigenesis, metastasis, and chemo and 
radioresistance.[14,15] Therefore, detecting and 
analyzing these cells among CTCs in circu-
lation could lead to better understanding of 
EMT, and tumor metastasis. CD133 expressed 
on the cell surface is now recognized as a pro-
spective marker for the isolation and charac-
terization of pancreatic stem and progenitor 
cells.[16–18] CD133+ pancreatic CSCs showed 
more aggressive behavior such as increased 
cell proliferation, migration, and invasion 
compared with the CD133− cells because 
they underwent EMT more readily.[19–21]
Detection and isolation of CTCs is chal-
lenging due to the low number of CTCs in 
the blood (on the order of 1 CTC per 106–109 
normal blood cells) and the biological het-
erogeneity of CTCs.[22] Multiple approaches 
have been considered to overcome the limi-
tation of low numbers of CTCs in periph-
eral blood, including immunoaffinity based 
methods, size-based separation, Ficoll density 
gradient, dielectrophoresis, negative deple-
tion, and inertial methods.[23] Microfluidic 
isolation techniques have become attractive 
since the development of the first microflu-
idic CTC Chip[4] due to their high sensitivity, 
high throughput, low cost, and enhanced 
spatiotemporal control abilities.[4,9] However, 
although antibody-based capture methods offer high specificity, 
most reported technologies lack the ability to capture biologi-
cally heterogeneous populations of CTCs. The main approach 
for enrichment thus far has been to capture cells of interest 
by using specific epithelial markers such as EpCAM on the 
cell surface to distinguish CTCs from leukocytes.[3] However, 
EpCAM-based approaches could potentially miss a substantial 
portion of CTCs that have lost expression of epithelial markers 
and have undergone the process of EMT.[11,24]
Herein, we present an integrated technology and biology-
based translational approach using two CTC Carpet Chips in 
sequence to identify and study the biological relevance of rare 
heterogeneous population of circulating cells, including both 
epithelial CTCs (EpCs) and EMT-like CTCs (EMTCs), simulta-
neously from the peripheral blood of PaCa patients (Figure 1). 
We have focused on a novel strategy based on obtaining sepa-
rate populations of phenotypically distinct CTCs.
Obtaining pure CTC populations is crucial for a robust down-
stream gene analysis. Herein, by applying the novel sequential 
microfluidic Carpet CTC Chip with different spacing between 
posts and arrays, we demonstrated enumeration, detection, 
and downstream mRNA genetic analysis of distinct CTC 
populations (EpCs and EMTCs) from PaCa patients. We profiled 
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Figure 1. Dual capture strategy using CTC Carpet Chip. Schematic of the CTC Carpet Chips 
connected in series. Rare CTCs including both circulating epithelial cells (EpCs, dark pink) and 
EMT-like cells (EMTCs, orange) were captured simultaneously from the peripheral blood of 
pancreatic cancer (PaCa) patients by using two markers of interest, anti-EpCAM and anti-CD133, 
in two different chips. The white/red blood cells are shown in green/red respectively. The posts 
are displayed in different colors only for visualization of the device pattern. The video showing the 
capture principle and approach is available in the Supporting Information (Supplementary Video 1).
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the mRNA expression of both of these populations using a panel 
of 96 cancer-related genes (Table S1, Supporting Information).
In the current work, for a more thorough representation of 
biologically diverse CTCs in patients with pancreatic cancer 
sequential microfluidic devices were set up using antibodies 
against EpCAM, to capture EpCAM+ CTCs, and antibodies 
against CD133 to capture more stem cell like cells, or putative 
EpCAM- CTCs.[25]
2. Results and Discussion
2.1. CTC Carpet Microfluidic Chip Technology
The CTC Carpet Chip is designed to capture heterogeneous 
populations of rare CTCs using antibody-coated microposts.[4] 
In order to increase the sensitivity of capture phenotypically 
distinct CTCs, the previous CTC-Chip design developed by 
Nagrath et al. was modified by implementing an 18° rotation 
of hexagonal arrays of 100 µm × 100 µm microposts with an 
average distance of 50 µm between them (Figure S3A, Sup-
porting Information). We have incorporated novel rearrange-
ments of the posts which greatly enhances the capture of 
EpCs on one chip, while reducing off-target capture, including 
EMTCs. This employs a dual immunoaffinity and physical dis-
crimination approach enabled by the lateral flow distribution 
and cell post interactions within the CTC Carpet Chip. The 
CTC Carpet Chip has around 80 000 microposts and the overall 
size of the microfluidic device is 44.6 mm × 16.9 mm. The 
design of the CTC Carpet Chip and representative SEM images 
of the microposts are shown (Figure 2A).
Successful capture of each population with high specificity 
and sensitivity was dependent on the flow velocities and shear 
forces within the device. The flow velocity was optimized to 
allow maximal contact between cells and microposts, while 
shear forces were sufficient to prevent nonspecific cell attach-
ment to posts. Different micropost geometries and arrange-
ments of the arrays and other parameters were explored in the 
process of optimization of the CTC Carpet Chip (Figures S2 
and S3, Supporting Information). The aspect ratio, spacing, 
angle, micropost distribution, along with streamlines were opti-
mized to increase capture efficiency for target cells while main-
taining minimal nonspecific binding. The velocity magnitude 
profile and particle tracing plot on a portion of the diamond 
shape of the CTC Carpet Chip are shown in Figure 2B,C. Cell 
trajectories (blue lines) are based on particle tracing and the 
end position of the cells is shown by red dots (Figure 2C). The 
simulations clearly had shown the lateral distribution of fluid 
around the Carpet design as well as effective cell post interac-
tions. The CTC Carpet Chip was fabricated using standard 
photolithography techniques to create a silicon mold, followed 
by PDMS replica molding, and functionalized as previously 
described (Figure S1, Supporting Information).[26]
2.2. Single/Dual CTC Carpet Chip Optimization
Four cancer cell lines with different levels of EpCAM expression 
and one cell line with high CD133 expression were used for 
testing and optimization of the CTC Carpet Chip: colon cancer 
line HT-29 and pancreatic cancer line Panc-1 (high EpCAM 
expression), prostate cancer line PC-3 (low EpCAM expres-
sion), breast cancer line Hs-578T (no EpCAM expression/nega-
tive control) and pancreatic cancer line Capan-1 (high CD133 
expression).[27] These cell lines were labeled with green Cell-
Tracker dye (GCT) (described in the supplementary) and spiked 
into blood at a concentration of 1000 cells mL−1 to test the cap-
ture efficiencies of the single CTC Carpet Chip functionalized 
with either anti-EpCAM or anti-CD133 antibodies. The CTC 
Carpet Chip yielded the following efficiencies across the dif-
ferent cell lines; 97.5% ± 2.2 (HT-29) and 94.9% ± 2.4 (Panc-1), 
87.7% ± 13.9 (PC-3), 13.6% (Hs-578T), and 73% ± 16.6 
(Capan-1) (Figure 3A). Thus, high capture efficiencies were 
observed using different cell lines using single CTC Carpet 
chip.
To capture different subpopulations of CTCs (EpCs and 
EMTCs) simultaneously from the same blood, we connected 
two devices functionalized with different antibodies (anti-
EpCAM in one device and anti-CD133 in the other device) 
in series as shown in Figure 3B. Therefore, distinct popula-
tions could be easily identified and separately made available 
for downstream gene analysis. Blood was passed through the 
connected chips at a flow rate of 1 mL h−1 through the inlet 
of the first device. Four different setups were tested in order 
to evaluate the sensitivity and specificity of the capture rates 
of the chips, each coated with and without the antibodies of 
interest (anti-EpCAM and anti-CD133), using Panc-1 spiked 
into blood. Chips coated with no antibodies (EpCAM− and 
CD133−) showed <3% capture efficiency (false positive). How-
ever, in the presence of antibodies (EpCAM+ and CD133+), 
efficiency rates increased to 89.8% ± 9.5 EpCAM+ cells and 
6.6% ± 3.3 CD133+ cells. EpCAM+ and CD133− dual chips 
showed 90.2% and 0.7% EpCAM+ and CD133+ cells capture 
efficiencies. EpCAM− and CD133+ dual chips captured 2.4% 
and 7.2% EpCAM+ and CD133+ cells capture efficiencies 
(Figure 3C), demonstrating high specificity and consistent 
yields for both of the captured antibodies in the dual isola-
tion. In summary, applying dual CTC Carpet chip technology 
in terms of isolating different type of cancer cells was quite 
sensitive and specific.
A pseudocolored SEM image of captured cancer cells spiked 
into blood on the CTC Carpet Chip is shown in Figure 3D. 
After capture, cancer cells were detected by immunofluores-
cence staining protocol described in Methods. Pan-CK+/CD45−/
DAPI+, and Vim+/CD45−/DAPI+ phenotypes were determined 
and enumerated as EpCs and EMTCs, respectively. Figure 3E 
shows confocal images of captured cancer cells stained for 
Pan-CK (red) and CD45 (green) to distinguish EpCs and 
WBCs. The captured EMTCs in the CD133 chip are shown 
in Figure 4C, with Vim (orange) and CD45 (green) used as 
detection antibodies for the EMTCs and WBCs respectively.
2.3. Application of Technology to Evaluate 
Heterogeneity in Clinical Samples
We used the microfluidic chip to analyze fresh blood samples 
from PaCa patients. Thirty-five patients with histologically 
Adv. Biosys. 2018, 2, 1800228
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Figure 2. Schematic representation of CTC Carpet Chip and finite element simulations. A) CTC Carpet Chip designed by AutoCAD software based on an 
18° rotation of hexagonal arrays of 100 µm posts. It has around 80 000 post patterns with dimension of 100 µm × 100 µm, the distance between each 
post is 50 µm in which the posts are distributed in a way to have lateral flow. B,C) Simulation studies were done by using COMSOL software to ensure the 
sensitivity and specificity of the designed chip. B) Velocity magnitude of flow on a portion of diamond shape of the CTC Carpet Chip. C Particle tracing plot 
around microposts near the inlet demonstrating typical streamlines (blue) and capture of 15 µm rigid particles (red) upon encountering a wall (post).
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documented PDAC of varying stages were analyzed, with 
clinical data provided in Table S2 (Supporting Information). 
Blood samples from nine healthy controls (HC) were used for 
comparison.
The dual CTC Carpet Chips were connected in the sequen-
tial order of EpCAM first followed by CD133 in order to capture 
the EpCs and EMTCs (Figure S4, Supporting Information) 
and then whole blood collected from the patients was flowed 
through the chips at 1 mL h−1 (Figure 3B). However, to increase 
the throughput in the future, one can apply a predepletion 
step like RBC removal using inertial separation utilizing spiral 
devices.[28]
Figure 4A,B shows representative images of EpCs cells 
(Figure 4A) on the EpCAM chip captured from PaCa patients. 
Adv. Biosys. 2018, 2, 1800228
Figure 3. CTC Carpet Chip cell line optimization. A) Capture efficiency (%) of cell lines with various levels of EpCAM expression including HT-29 
and Panc-1 (high EpCAM expression), PC-3 (low EpCAM expression), and Hs-578T (none), and one cell line with high CD133 expression (Capan-1). 
1000 green CellTracker (GCT) cells were spiked into blood and processed through single CTC Carpet Chip coated with anti-EpCAM or anti-CD133. 
B) Representative image showing dual CTC Carpet Chip; 1 mL blood was sent through the anti-EpCAM coated CTC Carpet Chip which was connected to 
the anti-CD133 coated CTC Carpet Chip in sequence. C) Capture efficiency (%) of Panc-1 cancer cells spiked into blood with or without antibodies (EpCAM 
and CD133) in the dual chips. The solid/hatched yellow and blue bars show the presence/absence of EpCAM and CD133 antibodies. D) Pseudocolored 
SEM image of the captured cancer cells spiked into blood on the CTC Carpet Chip. Cancer cells and WBCs are shown in red and green respectively. 
E) Confocal image of a typical CK+ cancer cell is shown here. The Pan-CK+ CTCs were detected with Pan-CK (red) along with a CD45+ (green) WBC.
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EpCs demonstrating varied morphologies, ranging from 
round to oval in shape and in some cases occurring as cluster 
(Figure 4B). Figure 4C shows images of an EMTC and a leuko-
cyte. As shown in Figure 4D, EMTCs captured on the chip had 
a wide range of cell sizes. Red, orange, and green arrows indi-
cate Pan-CK, Vim, and CD45 staining respectively. Figure 4E 
shows a representative confocal image of a EMTC (pink) and 
a WBC (green) captured from a PaCa patient on the CD133 
chip. To determine the presence of EpCs+ in the CD133 chip 
and EMTCs+ in the EpCAM chip, 16 patient samples were 
tested through triple staining of each chip (Pan-CK and Vim 
along with CD45) (Figure S5, Supporting Information). A small 
number of double positive (Pan-CK+/CD45+) cells were found 
in some samples and were excluded from this study due to 
unknown origin and significance.
We quantified the captured EpCs and EMTCs on EpCAM and 
CD133 chips and found that 97.5% of the patients had EpCs+ 
(≥5 Pan-CK+ CTCs mL−1) with a mean of 22.4 ± 17.7 mL−1, 
while all 35 patients had EMTCs (≥15 Vim+ CTCs mL−1) with a 
mean of 85.7 ± 59.5 per mL. In contrast, low numbers of EpCs 
(0.9 ± 0.9 per mL) and EMTCs (1.9 ± 2 per mL) were observed 
in the HCs (Figure 5A). In summary, the results indicate 
significant differences between the overall number of CTCs 
in PaCa patients samples (108.1 ± 63.5) versus HCs (2.8 ± 2.6) 
(p < 0.0001), as well as the number of EpCs (20.8% of overall 
CTCs) versus EMTCs (79.2% of overall CTCs). We found 
significantly higher numbers of EMT-like CTCs in circulation 
in PaCa patients compared to epithelial CTCs (p < 0.0001).
2.4. CTCs Enrichment by Using the CTC Carpet Chip  
to Explore Associations with Clinical Outcomes
To further explore the relationship of EpCs and EMTCs and 
clinical outcomes in the PaCa patient cohort (n = 35), the CTC 
counts from these two cell populations were analyzed based on 
clinical disease stages (Figure 5B–G). All stages except stage IIA 
showed significantly higher numbers of EMTCs compared to 
the number of EpCs (Figure 5B). Patients with stage IV disease 
showed higher numbers of EMTCs than EpCs (p = 0.0008), 
Adv. Biosys. 2018, 2, 1800228
Figure 4. Characterization of circulating epithelial CTCs (EpCs) and EMT-like CTCs (EMTCs) in the EpCAM and CD133 Carpet Chip from PaCa patients. 
A) EpCs and WBCs were stained with Pan-CK and CD45 respectively, in addition to DAPI. Red arrow is showing a Pan-CK EpC. B) An EpC cluster 
captured around the posts. Post outlines are marked in white circle and bright field. The post outlines are marked with white circles. C) Vimentin 
(orange) and CD45 (green) staining for detection of EMTCs and WBCs respectively. Orange and green arrows are showing Vimentin and CD45 positive 
cells respectively. D) Different sizes of EMTCs captured on the device. E) Confocal image of EMTC (pink) and WBC (green). All scale bars are 10 µm.
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suggesting the strong role of the EMT process in the metastatic 
progression of pancreatic cancer.[2,5,10,29–31]
Also, patients were categorized based on the tumor status as 
resectable (n = 9), borderline resectable (n = 2), locally advanced 
(n = 13), and metastatic (n = 11) groups. There were signifi-
cantly higher numbers of EMTCs than EpCs between all these 
groups, except borderline resectable patients due to the small 
sample numbers (Figure 5C). The ratio of EpCs/EMTCs to total 
number of CTCs has a decreasing/increasing trend with later 
stages (Figure 5D). The percentage of EpCs decreased toward 
late stages, whereas the percentage of EMTCs increased. 
Figure 5E–G summarizes the frequencies of EpCs and EMTCs 
characterized in different patient subgroups, including tumor 
size <2 cm versus >2 cm, no lymph node involvement (N0) 
versus lymph node involvement (N1), and nonmetastatic (M0) 
versus metastatic (M1) groups. Significantly higher numbers 
of EMTCs (p = 0.04) were observed when the patients were 
grouped based on lymph node involvement (N1) compared 
with no lymph node involvement (N0) patients. This supports 
the observations from other studies, where the associations 
of EMT with lymph node metastasis have been reported.[32–34] 
However, we were not able to observe any significant correla-
tion between CTC abundance, tumor size, metastatic burden, 
operability, and survival rate in this cohort which could be due 
to the limited sample size.
2.5. Gene Expression Profiling of EpCs and EMTCs 
by Quantitative Reverse Transcription Polymerase 
Chain Reaction (qRT-PCR)
RNA was extracted from captured CTCs and utilized for gene 
expression profiling by RT-qPCR. The gene expression profiles 
of CTCs isolated from blood samples of PaCa patients (n = 17) 
which were run through the dual CTC Carpet Chip are shown 
in Figure 6. Figure 6A presents the heat map of expression 
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Figure 5. Analysis of EpCs and EMTCs from PaCa patient samples. A) Enumeration of EpCs and EMTCs on the anti-EpCAM and anti-CD133 coated 
CTC Carpet Chips from PaCa patients (n = 35) along with healthy controls (HCs) (n = 9). Significant difference between the overall number of CTCs 
in PaCa patients samples (108.1 ± 63.5) versus HCs (2.8 ± 2.6) (p < 0.0001) was observed using unpaired t-tests (two-tailed). Significantly higher 
numbers of EMTCs (85.7 ± 59.5) compared to EpCs (22.4 ± 17.7) were observed (p < 0.0001) using paired t-tests (two-tailed) (n = 35). B,C) Analysis of 
number of EpCs and EMTCs recovered in PaCa patient samples (n = 35) based on their clinical disease stages from stage IIA (n = 6), IIB and III (n = 
17), and IV (n = 12), and based on tumor status (resectable (n = 9), borderline resectabale (n = 2), locally advanced (n = 13), and metastatic (n = 11)). 
No significant differences were observed in the effect of stage and resection on the number of EpCs and EMTCs using unpaired t-tests. D) Ratio of 
EpCs to total number of CTCs and ratio of EMTCs to total number of CTCs from early to advanced stage disease. E–G) Enumerated EpCs and EMTCs 
grouped according to tumor size (> or <2 cm) E), lymph node involvement (N0 or N1) F), and metastasis (M0 or M1) G). Unpaired t-tests were used to 
analyze the effect of tumor size, lymph node involvement, and metastasis. N1 group (n = 18) showed significantly higher number of EMTCs compared 
to N0 group (n = 13) (p = 0.04). No significant correlation between tumor size and metastatic burden were observed.
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levels of genes. Figure 6B presents the median log fold change 
of select genes with logFC > 1.5. Among these genes, ERCC1 
showed >1.5 logFC in the CTCs captured on EpCAM coated 
chip which is correlated with significantly better overall sur-
vival (OS) and progression free survival (PFS). The histological 
staining and immunohistochemistry (IHC) analysis of some 
of these markers in the primary PDAC tissues are shown in 
Figure S6 (Supporting Information).
Figure 6C–D presents box plots showing expression of sig-
nificant differential expression of genes in patient CTCs iso-
lated by EpCAM and CD133 chips. CXCR1 (p = 0.03) in the 
EpCAM chip (Figure 6C), and POU5F1 (or Oct-4) (p = 0.008) 
and MYC (p = 0.03) in CD133 chip (Figure 6D) were signifi-
cantly differentially expressed. Given the phenotypic differ-
ences we have observed between EpCs and EMTCs, it is not 
surprising that the stem cell related gene POU5F1 (OCT4) 
is highly expressed in EMTCs. Based on our results, over 
expression of this gene was significantly correlated with 
worse PFS.
Signaling pathways based on analysis of captured CTCs on 
EpCAM chip compared to CTCs on CD133 chip with iPath-
wayGuide suggested that these two genes (POU5F1 and MYC) 
were involved in signaling pathways regulating pluripotency of 
stem cells.
To further explore the gene signatures in different stages of 
disease, the patients were grouped based on their disease stages 
(Figure 7). The summary of selected genes (p < 0.05) is shown 
in the box plots. Stage IIA patients showed significant differen-
tial expression of genes including ATL1, BMi1, CD14, CDH2, 
ERCC1, MKi67, TTF1, and Vim compared to all other stages 
(Figure 7A-i). We also compared protein level expression of 
select differentially expressed markers by immunohistochem-
istry of primary tissues. The hematoxylin and eosin (H&E) 
staining of the primary PDAC tissues of early stage patients is 
shown in Figure 7A-ii. The corresponding primary tumor tis-
sues were highly positive (intensity of 3, 100% positivity) for 
BMi1 protein expression and moderate positive (intensity of 
2, 10% positivity) for MKi67 protein expression shown by IHC 
analysis (Figure 7A-iii).
PaCa patients in stages IIB&III showed significant differen-
tial expression of ALDH1A3, ESR1, KRT18, and KRT19 com-
pared to stage IIA (Figure 7B-i). Comparing stages IIB and III 
with stage IV patients reveled significant differential expression 
of genes including AKT1 and CD3D (Figure 7B-ii). Stage IV 
Adv. Biosys. 2018, 2, 1800228
Figure 6. Gene expression profiling in PaCa patients CTC samples (n = 17) based on capture device. A) Clustering heat map analysis of gene expression 
data based on CTCs captured by EpCAM versus CD133 CTC Carpet Chips was performed using −ΔCt. The top section shows the heat map of CTCs 
captured on EpCAM chip and the bottom section of the panel presents the CTCs captured on the CD133 chip. The color scale shown at the top 
illustrates the relative expression level of genes across the samples: red represents an expression level above the mean, blue represents expression 
lower than the mean. B) The median log fold change (logFC) of selected genes with logFC > 1.5 is shown in yellow (for the EpCAM chip) and blue 
(for the CD133 chip). Each fold change is calculated from the −∆2 tC . C,D) Box plot diagrams of significantly differently expressed individual genes in 
EpCAM chip, CXCR1 (p = 0.03) and POU5F1 or Oct4 (p = 0.008) and MYC (p = 0.03) in CD133 chip. Yellow and blue bars represent the EpCAM and 
CD133 chips respectively. The Wilcoxon signed-rank test was used in RNA expression for paired samples (n = 17).
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patients showed significantly elevated expression of CDH1, 
DCN, KRT19, PGR, and PIK3CA genes compared to the rest 
of the stages (Figure 7C-i). The H&E staining of the primary 
PDAC tissue of late stage PaCa patients is shown in Figure 7C-
ii. The protein expression of PIK3CA in the corresponding 
primary tumor tissues was moderate (intensity of 2, 20% posi-
tivity) (Figure 7C-iii).
2.6. Molecular Signature and Prognosis
In the cohort considered in this study, the median OS of 
all patients was 15 ± 10.2 months (2.5–33.7) and the median 
PFS was 5.6 ± 10.5 months (1.7–33.5). The survival estimated 
by Kaplan–Meier (KM) were significantly better for patients 
with high expression of AKT1 (21.1 vs 6 months, p = 0.08 for 
Adv. Biosys. 2018, 2, 1800228
Figure 7. Gene expression profiling of CTCs based on PaCa patients categorized by disease stage. A) Stage IIA samples (n = 5) compared to the rest 
of stages (n = 30) analysis. A-i) Box plot diagrams of significantly (p < 0.05) highly expressed individual genes in stage IIA CTC samples compared 
to the rest of stages including ATL1, BMi1, CD14, CDH2, ERCC1, MKi67, TTF1, and VIM genes, A-ii) the H&E staining image of the primary tumor 
tissues of early stage patient, A-iii) immunohistochemistry (IHC) analysis of the corresponding primary tumor tissues of early stage patients for BMi1 
and MKi67 protein expressions revealed diffuse and strong positivity for BMi1 (intensity of 3 in 100% tumor cells), and patchy moderate positivity for 
Mki67 (intensity of 2 in 10% tumor cells) protein expression. B) Box plot diagrams of significantly highly expressed individual genes in stage IIB&III 
CTC samples (n = 18) compared with the early stage (n = 5) including ALDH1A3, ESR1, KRT18, and 19 B-i), and AKT1 and CD3D genes when stage 
IIB, III (n = 18) compared with the late stage (n = 12) B-ii). C) Stage IV CTC samples (n = 12) compared to the rest of the stages (n = 23) showed 
significantly over expression of genes including, CDH1, DCN, KRT19, PGR, and PIK3CA C-i). The H&E staining image the primary tumor tissues of late 
stage patient C-ii). PIK3CA protein expressions revealed patchy moderate positivity for this gene (intensity of 2 in 20%tumor cells) protein expression 
with IHC of primary tumor tissues C-iii). (Original magnification: ×100). The Mann–Whitney test was used to quantify differences in RNA expression 
for nonpaired samples using the average −ΔCt value across both sample chips (n = 17).
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OS, and 11.6 vs 4.6 months, p = 0.03 for PFS), BMi1 (20.4 vs 
13.6 months, p = 0.04 for OS, and 9.2 vs 4.6 months for 
PFS), CDH2 (30.2 vs 14.8 months, p = 0.04 for OS, and 6.9 vs 
5.1 months for PFS), ERCC1 (22.3 vs 10.6 months, p = 0.04 
for OS, and 11.7 vs 4.6 months, p = 0.02 for PFS), IL8 (21.1 vs 
6 months, p = 0.08 for OS, and 11.6 vs 4.6 months, p = 0.03 for 
PFS), TTF1 (20.4 vs 12.8 months, p = 0.08 for OS, and 9.3 vs 
2.5 months, p = 0.04 for PFS), and TP53 (18 vs 11.4 months 
for OS, and 10 vs 4.6 months, p = 0.03 for PFS) (Figure 8A–G). 
The H&E staining of the primary PDAC tissue of a PaCa 
patient is shown in Figure 8H-i. IHC analysis of TP53 pro-
tein expression in the corresponding primary tumor tissue 
showed high positivity (intensity of 2, 90% positivity) of this 
marker (Figure 8H-ii). PaCa patients with higher expression 
of metastatic marker GEMIN2 (5 vs 18 months, p = 0.01* for 
OS, and 4.6 vs 7.7 months for PFS), and stem marker POU5F1 
(13.4 vs 20.4 months for OS, and 4.6 vs 10.1 months p = 0.04* 
for PFS) showed worse OS or PFS respectively (Figure 8I,J).
Among these analyzed genes, as mentioned before, BMi1, 
CDH2, ERCC1, and TTF1 which showed higher expression in 
early stage patients (stage IIA) compared to the rest of stages 
which were also significantly associated with prolonged OS 
and/or PFS. However, PaCa patients with higher expression 
of stem marker POU5F1 showed worse PFS. Overall, isolating 
different CTC populations separately may help us predict the 
patient’s outcome.
3. Conclusion
CTC detection based only on EpCAM might miss a substan-
tial number of other CTCs, which might have an aggressive 
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Figure 8. Relationship between CTC gene expression and prognosis. Comparison of Kaplan–Meier overall survival (OS) and progression free survival 
(PFS) graphs in all patient CTCs samples (n = 17) with low (blue) and high (red) expressions of selected genes are shown. The median expression of 
each genes (2 tC−∆ ) across all patients were used as cutoff points. Log-rank (Mantel–Cox) tests were used to analyze the Kaplan–Meier OS and PFS. 
A–G) Higher expression of genes including BMi1, CDH2, and ERCC1 in PaCa patients showed significantly greater OS (p = 0.04). Higher expression of 
genes including AKT1 (p = 0.03), ERCC1 (p = 0.02), IL8 (p = 0.03), TTF1 (p = 0.04), and TP53 (p = 0.03) were significantly correlated with prolonged PFS. 
H) The H&E staining image of i) the primary tumor tissue, ii) and TP53 marker showed diffuse positivity (intensity of 2 in 90% of tumor cells) of this 
marker in the corresponding primary tumor tissues. I–J) Patients with high expression of genes including, GEMIN2 (p = 0.01) and POU5F1 (p = 0.04) 
had a worse OS and PFS respectively compared with those with low expression of these genes. (Original magnification: ×100.)
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phenotype such as EMTCs.[11,35] We were able to detect distinct 
heterogeneous CTC population (EpCs and EMTCs) simultane-
ously from PaCa patient samples by utilizing the novel sequen-
tial microfluidic Carpet CTC Chip. Different spacing between 
posts and arrays, enabled us to increase the capture efficiencies 
(>97%) and purity (>76%), which is crucial for downstream 
gene analysis.
Recent advances have enabled the detection of CTCs in var-
ious cancer types, however, the clinical utility of CTCs in pan-
creatic cancer needs to improve.[36] By detecting and analyzing 
primary tumor-derived circulating tumor cells, we would obtain 
useful information about disease status noninvasively. This 
data could provide valuable information to improve diagnosis 
and treatment of pancreatic cancer. There have been no prior 
reports correlating the EpCs and EMTCs circulation in PaCa.
Hence, we have developed sequential microfluidic CTC 
Carpet Chip using antibodies against EpCAM, to capture 
EpCAM+ CTCs, and antibodies against CD133 to capture more 
stem cell like cells, or putative EpCAM− CTCs in simultane-
ously from the peripheral blood of PaCa patients.[25] Although, 
the current study are performed with sequential devices, once 
can combine both the chips into a single device with a multi-
layer fabrication approach. Our results indicate that enumera-
tion, detection, and molecular characterization of these CTC 
populations show a great promise as a diagnostic and thera-
peutic tool for detection of cancer and metastasis. Our findings 
on gene expression profiling of CTCs from early stage PaCa 
patients may improve prediction of survival and outcomes. 
Finally, based on our observations on EMTCs and lymph node 
involvement, targeting the genes involved in the EMT process 
and individualized therapy could reduce metastasis, thereby 
increasing the survival rate of PaCa patients.[29]
4. Experimental Section
Computational Analysis of the Microposts: Finite element simulations 
were performed in COMSOL Multiphysics 4.2 (Comsol Inc.) with 
an inlet flow rate of 1 mL h−1 on a portion of diamond shape of the 
CTC Carpet Chip. A symmetry boundary condition was applied on the 
two similar boundaries flanking the posts. A wall (no slip) boundary 
condition was applied on the post outlines. The particle tracing plot was 
simulated with rigid particles 15 µm in size with a condition of sticking 
to any encountered wall being applied.
Capture Efficiency of Single CTC Carpet Chip: Four different cancer cell 
lines with different EpCAM expression levels, colon cancer line HT-29, 
pancreatic cancer line Panc-1, prostate cancer line PC-3, and breast 
cancer line Hs-578T, and CD133 positive pancreatic cancer line Capan-1 
were fluorescently labeled with green CellTracker dye (GCT) (Invitrogen). 
To determine the percentage of cells captured on a functionalized CTC 
Carpet Chip, coated with either anti-EpCAM (for EpCAM expression cell 
lines) or anti-CD133 (for CD133 expression cell line), 1000 cells from 
each of the fluorescently labeled cancer cell lines were spiked into 
whole blood collected from HCs and flowed through the microfluidic 
device at a constant flow rate (1 mL h−1). Then cells were fixed and 
permeabilized on the chip by using Cytofix/Cytoperm (BD Bioscience) 
followed by staining with DAPI (Invitrogen) to identify DNA content. 
Capture efficiency was calculated as the percentage of captured cells 
on the device divided by the total number of cells flowed through the 
chip. Captured cancer cells were identified and enumerated by scanning 
the entire micropost chamber of the device using a Nikon Eclipse Ti 
fluorescence microscope.
Capture Efficiency of Dual CTC Carpet Chip: In order to facilitate 
separating circulating epithelial (EpCAM-expressing) and EMT-like 
(CD133-expressing) cells in different devices in sequential order from 
the same sample, two separate CTC Carpet Chips were connected to 
each other using a 2-inch piece of connective tubing (Fisherbrand Tygon 
S3 E-3603 Flexible Tubings). The first chip was coated with anti-EpCAM 
and the second one with anti-CD133. The blood sample was then 
processed through each chip in succession. After this step, the chips 
were disconnected from one another, and washed with PBS (10 mL h−1) 
for the immunofluorescence staining process.
Patient CTC Capture and Immunofluorescence Staining: This study was 
approved by the institutional review board (IRB) of the University of 
Michigan. 1 mL of whole blood from each PaCa patient was processed 
through two CTC Carpet Chips connected in series at the designated 
flow rate (1 mL h−1), followed by fixation and permeabilization with 4% 
paraformaldehyde (Pierce) and 0.2% Triton X-100 (Sigma) respectively, 
followed by blocking with 3% bovine serum albumin (BSA) (Sigma) plus 
2% goat serum (Invitrogen).
In order to identify and characterize subpopulations of CTCs and 
distinguish them from other blood cells, the following criteria were 
used: cells that were captured on the anti-EpCAM coated chip and 
stained positive for pan-cytokeratin (Pan-CK) (AbDSerotec), negative 
for CD45 (AbDSerotec), and positive for cell nucleus staining (DAPI) 
(Invitrogen) were characterized as EpCs; and cells that were captured on 
the anti-CD133 coated chip and stained positive for Vimentin (Vim) (BD 
Bioscience), negative for CD45, and positive for DAPI were characterized 
as EMTCs.[3] Alexa Fluor 488/546/647-conjugated secondary antibodies 
(Invitrogen) were applied in order to detect CD45, Pan-CK, and Vim 
respectively.
RNA Extraction and qRT-PCR Analysis: The mRNA extracted from 
CTCs were analyzed for gene expression for the selected panel of 96 
cancer-related genes (Table S2, Supporting Information). Isolated 
CTCs within the device were incubated at 42 °C for 30 min with 
extraction buffer (Arcturus PicoPure kit, Invitrogen) to lyse the cells. 
Then RNase free water was passed through the chip to collect the 
cell lysate. Total RNA was then prepared from the CTC lysate using 
the Arcturus PicoPure kit (Invitrogen) and was subjected to a reverse 
transcription reaction followed by 18 cycles of preamplification 
of cDNAs of 96 genes of interest using the pooled TaqMan Gene 
Expression Assays and Cell-to-CT Kit (Ambion, Invitrogen). Finally, 
the gene expression pattern of preamplified cDNAs was determined 
using TaqMan Gene Expression Assays for 96 genes and the BioMark 
HD qPCR platform (35 cycles). Nondetect values were replaced by 
a pseudo cycle number of 40 and in the analyzed samples typically 
out of 96 genes, around 50% of them showed positive data. Also 
a cut off n > 2 (greater than 2 patients displaying gene expression 
in each group for each gene) was applied when genes in different 
groups were compared to each other, and 75 of 96 genes met this 
criterion. GAPDH was used as an internal reference to normalize 
cycle threshold (Ct) values for the genes of interest by subtracting 
each gene expression value by GAPDH to generate a −ΔCt. Median 
fold changes were generated by dividing the median gene expression 
(2 C t−∆ ) of group A by that of group B. Finally, statistical analysis 
of data was done on the −ΔCt values for each gene in the studied 
samples.
Immunohistochemistry: A gastrointestinal pathologist reviewed 
each patient’s H&E stained resection specimen and identified a 
representative section of formalin-fixed, paraffin-embedded tumor, and 
normal tissue. The unstained 5 µm thick tissue section was reacted 
with anti-BMi1 (Cell Signaling), anti-MKi67 (Cell Marque), anti-PIK3CA 
(Abcam), anti-P53 (Cell Marque), MCAM (Abcam), and CD133 (Miltenyi 
Biotec) antibodies using IHC technique to determine levels of tumoral 
protein expression of BMi1, MKi67, PIK3CA, TP53, MCAM, and CD133. 
The staining intensity and percentage of positive cells out of total 
tumor cells were graded by a pancreatic pathologist who was blinded to 
patients’ outcomes. The intensity of IHC staining is graded on a scale 
of 0–3, where 0 is no staining, 1 is weak, 2 is moderate, and 3 is strong 
staining.
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Statistical Analysis: All results present as mean ± standard deviation. 
Unpaired t-tests (two-tailed) were used to compare the differences 
between total CTCs of patient samples (n = 35) versus healthy controls 
(n = 9). Paired t-tests (two-tailed) were used to compare the differences 
between EpCs and EMTCs (n = 35). Unpaired t-tests (two-tailed) were 
used to evaluate the effect of stage, resection, tumor size, lymph node 
involvement, and metastasis on EpCs and EMTCs levels (n = 35). 
Statistical significance was defined as a two-sided p < 0.05. The Wilcoxon 
signed-rank test was used in RNA expression for paired samples 
(n = 17). The Mann–Whitney test was used to quantify differences in 
RNA expression for nonpaired samples using the average −ΔCt value 
across both sample chips (n = 17). Analyses were conducted using 
GraphPad Prism, Python, R software environment, and iPathwayGuide 
(Advaita). p-values were not adjusted for multiple testing due to the 
small number of patient samples. The median expressions of genes 
(2 Ct−∆ ) across all patients were used as cutoff points for the Kaplan 
Meier graphs. Log-rank (Mantel–Cox) tests were used to analyze the 
Kaplan–Meier OS and PFS graphs in all patient CTCs samples (n = 17). 
p values threshold of 0.05 were used in the iPathwayGuide analysis.
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from the author.
Acknowledgements
This work was supported by the National Institutes of Health (NIH) 
Director’s New Innovator Award (1DP2OD006672-01) (SN), a 
Department of Defense (DoD) Office of the Congressionally Directed 
Medical Research Programs (CDMRP) Career Development Award 
(SN), and funding from the Lefkofsky Scholar award to S.N. The authors 
express their gratitude to all the patients who participated in this study 
and the healthy volunteers who contributed blood samples. The authors 
also thankfully acknowledge the clean room facility available at the Lurie 
Nanofabrication Facility and the Microscopy and Image Analysis (MIL) 
of the University of Michigan. IHC of primary tumors was performed 
by the Research Histology and Immunoperoxidase Laboratory at the 
University of Michigan Comprehensive Cancer Center under support of 
grant P30CA046592. The author would like to thank clinical specimen 
coordinator Kara Schradle and Kirk Herman. The authors are also 
grateful to Meggie Grafton and Mostafa Ghannad-Rezaie for their help 
in AutoCAD design of the devices, Saeedeh Noroozi, and Ali Attari for 
helping with animations images and video, Rork Kuick for his help with 
statistical analysis and review of the manuscript, and Molly Kozminsky 
and Ramdane Harouaka for reviewing the manuscript and giving 
valuable feedback.
Conflict of Interest
The authors declare no conflict of interest.
Keywords
circulating tumor cells (CTCs), EMT-like CTCs (EMTCs), epithelial-to-
mesenchymal transition (EMT), microfluidics, pancreatic cancer
Received: July 24, 2018
Revised: August 26, 2018
Published online: September 26, 2018
[1] R. L. Siegel, K. D. Miller, J. Ahmedin, CA: Cancer J. Clin. 2018, 
68, 7.
[2] K. Tjensvoll, O. Nordgard, R. Smaaland, Int. J. Cancer 2014, 134, 1.
[3] M. Alunni-Fabbroni, M. T. Sandri, Methods 2010, 50, 289.
[4] S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, 
L. Ulkus, M. R. Smith, E. L. Kwak, S. Digumarthy, A. Muzikansky, 
P. Ryan, U. J. Balis, R. G. Tompkins, D. A. Haber, M. Toner, Nature 
2007, 450, 1235.
[5] N. Bednarz-Knoll, C. Alix-Panabieres, K. Pantel, Cancer Metastasis 
Rev. 2012, 31, 673.
[6] T. Kurihara, T. Itoi, A. Sofuni, F. Itokawa, T. Tsuchiya, S. Tsuji, 
K. Ishii, N. Ikeuchi, A. Tsuchida, K. Kasuya, T. Kawai, Y. Sakai, 
F. Moriyasu, J. Hepatobiliary Pancreat Surg. 2008, 15, 189.
[7] N. Kanwar, S. Done,  2011, https://doi.org/10.5772/23385.
[8] S. L. Stott, C. H. Hsu, D. I. Tsukrov, M. Yu, D. T. Miyamoto, 
B. A. Waltman, S. M. Rothenberg, A. M. Shah, M. E. Smas, 
G. K. Korir, F. P. Floyd, A. J. Gilman, J. B. Lord, D. Winokur, 
S. Springer, D. Irimia, S. Nagrath, L. V. Sequist, R. J. Lee, 
K. J. Isselbacher, S. Maheswaran, D. A. Haber, M. Toner, Proc. Natl. 
Acad. Sci. USA 2010, 107, 18392.
[9] Z. Zhang, S. Nagrath, Biomed. Microdev. 2013, 15, 595.
[10] C. L. Chen, D. Mahalingam, P. Osmulski, R. R. Jadhav, C. M. Wang, 
R. J. Leach, T. C. Chang, S. D. Weitman, A. P. Kumar, L. Z. Sun, 
M. E. Gaczynska, I. M. Thompson, T. H. M. Huang, Prostate 2013, 
73, 813.
[11] K. Pantel, C. Alix-Panabieres, Trends Mol. Med. 2010, 16, 398.
[12] R. J. Torphy, C. J. Tignanelli, R. A. Moffitt, S. A. Soper, J. J. Yeh, 
J. Am. College Surg. 2013, 217, S30.
[13] A. Satelli, S. L. Li, Cell. Mol. Life Sci. 2011, 68, 3033.
[14] I. Nel, U. Jehn, T. Gauler, A.-C. Hoffmann, Transl. Lung Cancer Res. 
2014, 3, 100.
[15] L. Xu, Front. Biosci., Landmark Ed. 2013, 18, 795.
[16] Y. Hori, Adv. Exp. Med. Biol. 2013, 777, 185.
[17] J. Hatina, Neoplasma 2012, 59, 700.
[18] J. Hatina, W. A. Schulz, J. Fischer, J. Wahl, K. M. Debatin, 
C. Beltinger, Dtsch. Med. Wochenschr. 2007, 132, 1629.
[19] T. Moriyama, K. Ohuchida, K. Mizumoto, L. Cui, N. Ikenaga, 
N. Sato, M. Tanaka, Cancer 2010, 116, 3357.
[20] Y. Zhang, J. S. Wei, H. Wang, X. F. Xue, Y. An, D. Tang, Z. X. Yuan, 
F. T. Wang, J. L. Wu, J. J. Zhang, Y. Miao, Oncol. Rep. 2012, 27, 
1599.
[21] Q. Ding, M. Yoshimitsu, T. Kuwahata, K. Maeda, T. Hayashi, 
T. Obara, Y. Miyazaki, S. Matsubara, S. Natsugoe, S. Takao, 
Hum. Cell 2012, 25, 1.
[22] M. Liberko, K. Kolostova, V. Bobek, Crit. Rev. Oncol. Hematol. 2013, 
88, 338.
[23] C. Alix-Panabieres, K. Pantel, Nat. Rev. Cancer 2014, 14, 623.
[24] T. M. Gorges, I. Tinhofer, M. Drosch, L. Röse, T. M. Zollner, 
T. Krahn, O. v. Ahsen,  2012.
[25] Q. Ding, Y. Miyazaki, K. Tsukasa, S. Matsubara, M. Yoshimitsu, 
S. Takao, Mol. Cancer 2014.
[26] V. Murlidhar, M. Zeinali, S. Grabauskiene, M. Ghannad-Rezaie, 
M. S. Wicha, D. M. Simeone, N. Ramnath, R. M. Reddy, S. Nagrath, 
Small 2014, 10, 4895.
[27] H. J. Lee, D. D. You, D. W. Choi, Y. S. Choi, S. J. Kim, Y. S. Won, 
H. J. Moon, J. Korean Surg. Soc. 2011, 81, 263.
[28] H. Chen, Sci. Rep. 2018, 8, 4042.
[29] M. Beuran, I. Negoi, S. Paun, A. D. Ion, C. Bleotu, R. I. Negoi, 
S. Hostiuc, Pancreatology 2015, 15, 217.
[30] F. H. Sarkar, Y. Li, Z. Wang, D. Kong,  2009.
[31] Z. Y. Zhang, H. Y. Ge, Cancer Lett. 2013, 336, 34.
[32] S. Yamada, B. C. Fuchs, T. Fujii, Y. Shimoyama, H. Sugimoto, 
S. Nomoto, S. Takeda, K. K. Tanabe, Y. Kodera, A. Nakao, Surgery 
2013, 154, 946.
Adv. Biosys. 2018, 2, 1800228
www.adv-biosys.comwww.advancedsciencenews.com
1800228 (13 of 13) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
[33] G. Lahat, N. Lubezky, S. Loewenstein, E. Nizri, S. Gan, 
M. Pasmanik-Chor, L. Hayman, E. Barazowsky, M. Ben-Haim, 
J. M. Klausner, Ann. Surg. Oncol. 2014, 21, 750.
[34] K. Hiroshi, T. Sonshin, M. Kosei, M. Yuko, K. Taisaku, M. Koki, 
D. Qiang, S. Masahiko, I. Satoshi, I. Sumiya, U. Shinichi, 
S. Hiroyuki, N. Shoji, J. Surg. Oncol. 2012, 105, 655.
[35] A. D. Rhim, E. T. Mirek, N. M. Aiello, A. Maitra, J. M. Bailey, 
F. McAllister, M. Reichert, G. L. Beatty, A. K. Rustgi, 
R. H. Vonderheide, S. D. Leach, B. Z. Stanger, Cell 2012, 148, 
349.
[36] S. Nagrath, R. M. Jack, V. Sahai, D. M. Simeone, Gastroenterology 
2016, 151, 412.
Adv. Biosys. 2018, 2, 1800228
